Accéder au contenu
Merck

Transcription factor binding at Ig enhancers is linked to somatic hypermutation targeting.

European journal of immunology (2019-12-11)
Ravi K Dinesh, Benjamin Barnhill, Anoj Ilanges, Lizhen Wu, Daniel A Michelson, Filip Senigl, Jukka Alinikula, Jeffrey Shabanowitz, Donald F Hunt, David G Schatz
RÉSUMÉ

Secondary diversification of the Ig repertoire occurs through somatic hypermutation (SHM), gene conversion (GCV), and class switch recombination (CSR)-three processes that are initiated by activation-induced cytidine deaminase (AID). AID targets Ig genes at orders of magnitude higher than the rest of the genome, but the basis for this specificity is poorly understood. We have previously demonstrated that enhancers and enhancer-like sequences from Ig genes are capable of stimulating SHM of neighboring genes in a capacity distinct from their roles in increasing transcription. Here, we use an in vitro proteomics approach to identify E-box, MEF2, Ets, and Ikaros transcription factor family members as potential binders of these enhancers. ChIP assays in the hypermutating Ramos B cell line confirmed that many of these factors bound the endogenous Igλ enhancer and/or the IgH intronic enhancer (Eμ) in vivo. Further investigation using SHM reporter assays identified binding sites for E2A and MEF2B in Eμ and demonstrated an association between loss of factor binding and decreases in the SHM stimulating activity of Eμ mutants. Our results provide novel insights into trans-acting factors that dictate SHM targeting and link their activity to specific DNA binding sites within Ig enhancers.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-β-actine antibody produced in mouse, clone AC-74, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Poly(deoxyadenylic-thymidylic) acid sodium salt, double-stranded alternating copolymer
Sigma-Aldrich
L-Histidinol dihydrochloride, ≥98 (TLC)